Evidence map›Paper›PMID 40360446›Full record

SynthesisEuropean journal of heart failure2025

Effect of pulmonary artery pressure-guided management on outcomes of patients with heart failure outside clinical trials: A systematic review and meta-analysis of real-world evidence with the CardioMEMS Heart Failure System.

Chris J Kapelios, Sotiria Liori, Michael Bonios, William T Abraham, Gerasimos Filippatos

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Heart failure evidence update 2026.Heart failure reviews · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chris J KapeliosHeart Failure Unit, Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Sotiria LioriHeart Failure Unit, Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Michael BoniosHeart Failure and Transplant Unit, Onassis Cardiac Surgery Centre, Attica, Greece.
William T AbrahamDivision of Cardiology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Gerasimos FilippatosHeart Failure Unit, Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.ORCID https://orcid.org/0000-0002-5640-0332

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsPulmonary artery pressure (PAP)-guided heart failure (HF) management using the CardioMEMS HF System improves patient outcomes in randomized controlled trials (RCTs). Our aim was to systematically assess its impact on outcomes of HF patients receiving the device in a non-RCT setting. METHODS AND

resultsPubMed, ClinicalTrials.gov and Cochrane Clinical Trial Collection were searched on 8 January 2025. Studies were eligible if they included: (i) pre/post-comparison of outcomes in patients receiving CardioMEMS; (ii) adult patients diagnosed with HF; (iii) follow-up ≥6 months, and (iv) report of the primary outcome, i.e. HF hospitalization (HFH) rates. Other outcomes were changes in PAP, New York Heart Association (NYHA) class and quality of life. Quantitative analysis was performed by generating forest plots and calculating pooled means, mean differences and incidence rate ratio (IRR) by random-effect models, as appropriate. Eight studies with a total of 3306 patients were included. Four studies were single-arm, open-label, industry-funded studies and four real-world practice studies. Four studies were performed in the US and four in Europe. Significant decreases in systolic PAP (-7.8 mmHg [-10.1 mmHg; -5.6 mmHg]), mean PAP (-5.2 mmHg [-6.7 mmHg; -3.8 mmHg]) and diastolic PAP (-4.4 mmHg [-5.5 mmHg; -3.3 mmHg]) were demonstrated. One year after CardioMEMS implantation, 56% [43%; 67%] of patients were NYHA class I/II with EQ-5D-5L visual analogue scale scores being significantly improved from baseline (7.2 [3.5; 10.9]). PAP-guided HF management was associated with a significant, 61% decrease in HFHs at 1 year (IRR 0.39 [0.31; 0.47]).

conclusionsHeart failure management with CardioMEMS leads to lower PAP, improved functional status and quality of life, and decrease of HFHs at 1 year in patients receiving the device in a real-life, non-RCT setting. SYSTEMATIC REVIEW REGISTRATION: PROSPERO database registration number CRD42025635206.

Indexed as

Disease ManagementHeart FailurePulmonary ArteryPulmonary Wedge PressureHumansQuality of LifeCardioMEMSHeart failure managementHemodynamicsHospitalizationPulmonary artery pressureTelemonitoring

Identifiers

PMID40360446
PMCPMC12575415

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.